Alliance Global Partners initiated coverage of Merus (MRUS) with a Buy rating and $90 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus N.V. Reports Q2 2025 Financial Results
- Merus’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating
- Optimistic Buy Rating for Merus Driven by Future Data on Petosemtamab in CRC
- Merus’s Strategic Advances in Biotechnology: Buy Rating Driven by Promising mCRC Data Outlook and Innovative Trial Designs
- Merus reports Q2 EPS ($2.23), consensus ($1.15)